TB-500 and Thymosin Beta-4 Explained

TB-500 is often sold as a "recovery peptide" and paired with BPC-157. Its name suggests it is the same as thymosin beta-4, a natural protein that has been studied in people. The two are related, but they are not the same thing, and that difference matters when you read claims online.

Key takeaways

• Thymosin beta-4 (Tβ4) is a natural 43-amino-acid protein found in almost every cell. It helps manage actin, a protein involved in cell movement and structure.
• TB-500 is usually a short synthetic fragment based on one active region of Tβ4. Products labeled TB-500 can vary.
• Full-length Tβ4 has been tested in some human clinical trials, such as eye drops for eye surface conditions. None led to FDA approval.
• For the TB-500 fragment, FDA said it identified no human exposure data.
• Neither is FDA-approved. A July 2026 advisory vote on TB-500 is not final and is not an approval.

Thymosin beta-4: the natural protein

Thymosin beta-4 was first found in the thymus gland, but it is present in most tissues and in blood platelets and wound fluid. Its main known job is to bind actin, which cells use to move and change shape. Because moving cells is central to wound repair, researchers became interested in whether extra Tβ4 could help healing.

In lab and animal studies, researchers have reported that Tβ4 may:

• Help cells migrate into wounds
• Support new blood vessel growth
• Reduce inflammation in some injury models
• Protect heart tissue after injury in animal models

These are early findings. They show biology worth studying, not proven treatments.

TB-500: the fragment

"TB-500" is a name used mostly in the research-chemical and veterinary world. It commonly refers to a short synthetic peptide based on the part of Tβ4 that binds actin. FDA describes it as "thymosin beta-4 fragment (LKKTETQ)," a 7-amino-acid sequence. Some sellers use the TB-500 name for other versions, which adds to the confusion.

A fragment is not the same as the full protein. It may behave differently in the body, last a different amount of time and have different side effects. So when a website cites a study on full-length Tβ4 to support TB-500, the evidence does not transfer automatically.

What human research exists

Full-length thymosin beta-4

A drug developer tested Tβ4 eye drops (called RGN-259) in clinical trials for eye surface problems such as dry eye and neurotrophic keratopathy, a condition where the cornea heals poorly. A phase III trial in neurotrophic keratopathy, published in a peer-reviewed journal, reported signs of improved healing and comfort compared with placebo. It was a small trial, and larger confirmatory studies were still needed. These were small, specialized trials of an eye drop, not injections for muscles or tendons. As of this writing, no Tβ4 product has been approved by the FDA.

Researchers have also explored Tβ4 for heart and skin wounds in early studies. None of this has produced an approved therapy.

The TB-500 fragment

FDA's compounding safety page states that for thymosin beta-4 fragment (TB-500), it "identified no human exposure data" and lacks important safety information. In other words, there are no published human studies showing that TB-500 heals injuries, and no human safety data to rely on.

Safety questions

Because human data on TB-500 are missing, the concerns are mostly unknowns:

• Immune reactions. FDA cited possible immunogenicity from aggregation and impurities.
• Blood vessel and cell growth. The same effects that may help healing raise theoretical questions for people with cancer or a history of it. This has not been studied in people.
• Product quality. "Research use only" products are not made for human use. What is in the vial may not match the label, and sterility is not guaranteed. See our post on research-use-only peptides.
• Stacking. TB-500 is often sold with BPC-157. That combination has no published human trials.

Where TB-500 stands with the FDA (October 2026)

• Not FDA-approved.
• Category 2 change. FDA's compounding safety-risk page now lists the TB-500 nomination as withdrawn by the nominators, while still describing the safety gaps above.
• Advisory committee vote. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee considered TB-500 for wound healing. It narrowly recommended adding it to the 503A bulks list. FDA staff scientists had recommended against it.
• Not final. The vote is advisory. As of mid-October 2026, an interim access policy for certain peptides had been sent for White House review but had not been issued, and no peptide had been added to the bulks list.

Our post on FDA bulk drug substance categories explains what these steps mean. Even if compounding becomes allowed, that would not mean TB-500 is proven to work or safe.

Sports and testing

The 2026 WADA Prohibited List bans "thymosin-β4 and its derivatives e.g. TB-500" at all times. Tested athletes should avoid it entirely.

A better starting point for recovery

For injuries, the steps with real evidence are a correct diagnosis, physical therapy, gradual return to load, sleep and enough protein. If you are curious about TB-500, a licensed provider can explain what is known and not known. Our telehealth guide covers how to find one.

The bottom line

Thymosin beta-4 is a real, natural protein with some early human research, mainly in eye drops. TB-500 is a lab-made fragment with no human exposure data that FDA could identify. Neither is FDA-approved, and a 2026 advisory vote did not change that. Treat TB-500 claims with care.

Sources

• FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
• FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
• 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution in Neurotrophic Keratopathy: Phase III Trial, PMC
• Holland & Knight: Peptides at a Crossroads (October 2026)
• World Anti-Doping Agency: The Prohibited List (2026)

Frequently asked questions